优时比的动态

FROM MASTERCLASSES APP+: Dr. Joseph F. Merola, M.D. MMSc, Co-Director of Masterclasses in Dermatology, discusses what makes the interdisciplinary Masterclasses APP+ meeting unique. Watch here: https://ow.ly/PO7i50U0KKR Masterclasses in Dermatology

FROM MASTERCLASSES APP+: Monica Richey discusses the future of APPs in the rheumatology space and how these clinicians may fill a shortage of rheumatologists in rural areas in the coming years and how rheumatology APPs can collaborate with dermatology practitioners. Watch here: https://ow.ly/P4lr50U0Oo5 Masterclasses in Dermatology

Masterclasses in Psoriatic Disease for APP+ provides CME accreditation for physicians and their extenders in dermatology and rheumatology. Educational Objectives: - Understand the link between psoriatic disease pathophysiology and treatment mechanisms. - Review roles of current and emerging treatments for psoriatic disease and co-morbidities. - Develop collaborative care strategies for managing psoriatic patients with systemic issues

Our full-slide summary of the Gordon et al. study “Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: pooled data from up to 3 years of treatment in randomized phase III trials” is now live on the #IMIDforum ! The Immune-Mediated Inflammatory Disease Forum is a valuable resource for keeping you up to date with hand-selected dermatology publications. Visit the website to view this content and more #PsO #Bimekizumab #Safety https://ow.ly/osVz50RAfrp

NEW TREATMENTS = NEW RESEARCH = NEW THINKING ABOUT DISEASE STATES. FINALLY SEBORRHEIC DERMATITIS IS GETTING SOME LONG-DESERVED ATTENTION AS A STAND ALONE DISEASE STATE. SOMEHOW WE ALL KNEW IT. NOW WE HAVE SOME DATA TO BETTER EXPLAIN IT. The "journey" of seborrheic dermatitis (SD) is showing signs of coming around full circle. The puzzle was left unfinished for about 2 decades after research implicating Malassezia spp as the "root cause" of SD did not fully make sense as an explanation. Just like a good unfinished mystery story come to light over time, new pieces of the puzzle emerge that help explain more clearly the basis of what we see and treat as clinicians. Dr. Chovatiya takes a shot at discussing where our understanding of SD is right now, and does a great job of explaining how the pieces of the puzzle are coming together. In my mind, having been close to it for so long, it is often good to step back and take a fresh look at something we have seen in front of us for a long time. It took just a few pieces of new fundamental data and analysis to open our eyes beyond being stuck in the same recycled dogma. SD has been given a makeover which has been long overdue. More to come from Dr. Raj C I am sure, and many of the rest of us who are stimulated by the desire to better understand and manage chronic inflammatory skin diseases. See the repost below.

Dr. Han discusses the importance of special-site trials when evaluating treatments for psoriasis in areas such as a scalp and palmoplantar area. https://ow.ly/mFLg50U0OXh Masterclasses in Dermatology

FROM MASTERCLASSES APP+: Joseph F. Merola, M.D. MMSc, discusses lessons from the Masterclasses meeting that can help both dermatologists and rheumatologists improve their treatment of psoriatic disease. Watch now: https://ow.ly/L3Qj50U0OFh Masterclasses in Dermatology

#publication update: We worked closely with our amazing translational med team to understand IRAK4 signaling in HS patients. The publication focuses on noninterventional study that enrolled 30 patients with HS. #tpd #medicine #immunology #drugdevelopment #proteomics https://lnkd.in/eCipUteB

Long-term clinical trial results from a JAK inhibitor in #AlopeciaAreata (AA) patients, which includes integrated efficacy (through 104 weeks) and safety (up to 3.6 years) data, are published in the Journal of the European Academy of Dermatology and Venereology. Learn about long-term treatment results of severe AA with a JAK inhibitor in this manuscript: https://e.lilly/3SV3OD3

We’re leveraging our deep scientific expertise to develop next-generation oral small molecule degrader medicines in #immunology, and?we’re thrilled to share the findings from our non-interventional trial in the Journal of Investigative Dermatology! This #publication highlights the role of IRAK4 signaling in HS and the transformative potential of IRAK4 degradation to address TLR/IL-1R-driven immunological diseases. Read more: https://bit.ly/3SsRmv2 #RevolutionizingImmunology #TPD #DrugDevelopment??